MingMed
Nansha
About MingMed
MingMed is a Chinese company with global competitiveness in independent drug research and development. The company's main product pipeline includes, among other things, ophthalmic drugs, recombinant protein botulinum toxin, tumor immune drugs, and pet immune drugs, as well as a number of potential First-in-Class innovative drugs that have reached the clinical stage.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $110.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2021)
- Website: ming-med.com
- Phone: [email protected]
Industries & Categories
Health Care, Medical, Product Research
Canonical: https://fsome.com/organization/mingmed-87410 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.